A Comparison Study of LY2140023 and Aripiprazole in Schizophrenia Patients

• Proportion of participants with clinically significant weight change [ Time Frame: Baseline, 24 weeks ] [ Designated as safety issue: Yes ]
• Change from baseline up to 24 weeks in Barnes Akathisia Scale (BAS) [ Time Frame: Baseline, up to 24 weeks ] [ Designated as safety issue: Yes ]
• Change from baseline up to 24 weeks in Simpson-Angus Scale (SAS) [ Time Frame: Baseline, up to 24 weeks ] [ Designated as safety issue: Yes ]
• Change from baseline up to 24 weeks in Abnormal Involuntary Movement Scale (AIMS) [ Time Frame: Baseline, up to 24 weeks ] [ Designated as safety issue: Yes ]
• Change from baseline up to 24 weeks in Positive and Negative Syndrome Scale (PANSS) total and subscale scores [ Time Frame: Baseline, up to 24 weeks ] [ Designated as safety issue: No ]
• Change from baseline up to 24 weeks in EuroQol-5 Dimensions Questionnaire (EQ-5D) [ Time Frame: Baseline, up to 24 weeks ] [ Designated as safety issue: No ]
• Schizophrenia Resource Utilization Module (S-RUM) [ Time Frame: Baseline to 24 weeks ] [ Designated as safety issue: No ]
• Change from baseline up to 24 weeks in Subjective Well-Being Under Neuroleptic Treatment Scale- Short Form (SWN-S) total score and domain scores [ Time Frame: Baseline, up to 24 weeks ] [ Designated as safety issue: No ]
• Change from baseline up to 24 weeks in Personal and Social Performance (PSP) Score [ Time Frame: Baseline, up to 24 weeks ] [ Designated as safety issue: No ]
• Change from baseline up to 24 weeks in Clinical Global Impression-Severity Scale (CGI-S) [ Time Frame: Baseline, up to 24 weeks ] [ Designated as safety issue: No ]
• Change from baseline up to 24 weeks in 16-Item Negative Symptom Assessment (NSA-16) [ Time Frame: Baseline, up to 24 weeks ] [ Designated as safety issue: No ]
• Number of Participants with 30% decrease in PANSS total score [ Time Frame: Baseline up to 24 weeks ] [ Designated as safety issue: No ]
• Number of Participants with suicidal behaviors and ideations measured by Columbia Suicide Severity Rating Scale (CSSRS) [ Time Frame: Baseline to 24 weeks ] [ Designated as safety issue: Yes ]
• Time to discontinuation [ Time Frame: Baseline up to 24 weeks ] [ Designated as safety issue: Yes ]

The purpose of this study is to determine whether weight gain will be significantly less in LY2140023 than aripiprazole in patients with schizophrenia.

• Drug: LY2140023
  Administered orally
• Drug: Aripiprazole
  Administered orally

• Experimental: LY2140023
  Double Blind Phase: 40 mg administered orally, given twice daily for 24 weeks. Dose may be adjusted to a minimum of 20 mg and a maximum of 80 mg. Open Label Phase: 40 mg administered orally, given twice daily for an additional 28 weeks.
  Intervention: Drug: LY2140023
• Active Comparator: Aripiprazole
  Double Blind Phase: 15 mg administered orally, given once daily for 24 weeks. Dose can be adjusted to a minimum of 10 mg or a maximum of 30 mg. Open Label Phase: LY2140023, 40 mg administered orally, given twice daily for an additional 28 weeks.
  Interventions:

  • Drug: LY2140023
  • Drug: Aripiprazole

Inclusion Criteria:

• Clinical diagnosis of schizophrenia
• Female patients of childbearing age must test negative for pregnancy at screening and agree to use single, effective, medically acceptable method of birth control
• Patients must require initiation of or modification to current antipsychotic treatment as outpatients
• Patients must be considered reliable, have a level of understanding sufficient to perform all tests and examinations required by the protocol, and be willing to perform all study procedures
• Patients must be able to understand the nature of the study and have given their own informed consent

Exclusion Criteria:

• Have been on treatment with aripiprazole in the past 2 months or are aripiprazole nonresponders
• Patients who are pregnant, nursing, or intend to become pregnant within 30 days of completing the study
• Hospitalized within 2 weeks of screening or have been hospitalized for an exacerbation of symptoms of schizophrenia with a discharge date in the past 2 months
• Patients who are actively suicidal
• Patients with uncorrected narrow-angle glaucoma, history of or current seizure disorder, uncontrolled diabetes, certain diseases of the liver, renal insufficiency, uncontrolled thyroid condition or other serious or unstable illnesses
• Patients who have had electroconvulsive therapy (ECT) within 3 months prior to screening or will have ECT at any time during the study
• Patients with known medical history of Human Immunodeficiency Virus positive (HIV+) status
• Test positive for (1) Hepatitis C virus antibody or (2) Hepatitis B surface antigen (HBsAg) with or without positive Hepatitis B core total antibody
• Patients with a corrected QT interval (Bazett's; QTcB)>450 msec (male) or >470 msec (female) at screening
• Patients who have a history of inadequate clinical response to antipsychotic treatment for schizophrenia
• Patients who have received treatment with any depot formulation of an antipsychotic medication within 1 dosing interval, minimum of 4 weeks, prior to screening
• Are currently enrolled in, or discontinued within the last 60 days from, a clinical trial involving an investigational product or unapproved use of a drug or device, or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study
• Have any other psychiatric diagnoses in addition to schizophrenia
• Have previously completed or withdrawn from this study, or any other study investigating LY2140023 or any predecessor molecules with glutamatergic activity
• Patients who have received an adequate treatment trial, in the opinion of the investigator, with clozapine at doses greater than 200 mg daily within 12 months prior to screening, or who have received any clozapine at all during the month before screening
• Diagnosis of substance-induced psychosis within 7 days of screening (or at any time during the study)